Eton Pharmaceuticals (NASDAQ:ETON) Trading Up 5.8% Following Analyst Upgrade

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) shares traded up 5.8% on Thursday after Zacks Research upgraded the stock from a hold rating to a strong-buy rating. The stock traded as high as $20.06 and last traded at $20.1280. 195,300 shares were traded during trading, a decline of 27% from the average session volume of 267,891 shares. The stock had previously closed at $19.02.

Several other equities research analysts have also issued reports on the stock. Wall Street Zen raised shares of Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday. Craig Hallum upped their price target on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Friday. HC Wainwright increased their price target on Eton Pharmaceuticals from $37.00 to $52.00 and gave the company a “buy” rating in a research note on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Thursday, January 22nd. Finally, B. Riley Financial upped their target price on Eton Pharmaceuticals from $26.00 to $31.00 and gave the stock a “buy” rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $39.33.

Key Stories Impacting Eton Pharmaceuticals

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Several brokerages raised price targets and reiterated buy ratings (HC Wainwright to $52, B. Riley to $31, Craig Hallum to $35), increasing upside expectations and driving bullish investor sentiment. Analyst Upgrades
• Positive Sentiment: Eton acquired U.S. rights to HEMANGEOL, expanding its commercial portfolio in a specialty/rare-disease area and creating a clearer near-term revenue pathway. Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL
• Positive Sentiment: Market commentary highlights a meaningful consensus upside — Zacks notes analysts’ mean targets imply roughly a 49% rally — reinforcing the bullish narrative from upgraded targets. Does Eton Pharmaceuticals Have the Potential to Rally 49.25%?
• Neutral Sentiment: Earnings call and company commentary emphasized record revenue growth and commercial progress, which supports the growth story but did not fully offset margin pressures. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Reported short-interest data for March appears anomalous/flat (0 shares reported and a 0.0 days-to-cover), so it’s unlikely to be a material driver of today’s move. (Data looks unreliable.)
• Negative Sentiment: Q4 results: revenue beat slightly ($21.28M vs. $20.58M est.) but EPS missed ($0.05 vs. $0.12 est.); the company still reports negative net margin and negative ROE, raising profitability concerns. Eton Pharmaceuticals Reports Q4 & Full-Year 2025 Results
• Negative Sentiment: Analyst coverage also flagged the EPS miss in headlines (Zacks: earnings lag estimates), which could cap near-term sentiment until margins improve. Eton Q4 Earnings Lag Estimates

Institutional Trading of Eton Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Divisadero Street Capital Management LP acquired a new position in Eton Pharmaceuticals during the 2nd quarter worth about $7,092,000. Cannell Capital LLC increased its stake in shares of Eton Pharmaceuticals by 17.3% in the third quarter. Cannell Capital LLC now owns 455,405 shares of the company’s stock valued at $9,896,000 after buying an additional 67,230 shares during the period. Jefferies Financial Group Inc. bought a new position in shares of Eton Pharmaceuticals during the third quarter worth about $1,922,000. Lumbard & Kellner LLC bought a new position in shares of Eton Pharmaceuticals during the third quarter worth about $3,831,000. Finally, Diametric Capital LP lifted its stake in shares of Eton Pharmaceuticals by 333.0% in the second quarter. Diametric Capital LP now owns 84,858 shares of the company’s stock worth $1,209,000 after acquiring an additional 65,261 shares during the period. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Price Performance

The firm has a market capitalization of $598.58 million, a P/E ratio of -123.99 and a beta of 1.19. The company has a fifty day moving average of $16.72 and a 200 day moving average of $17.38. The company has a debt-to-equity ratio of 1.19, a current ratio of 1.63 and a quick ratio of 1.25.

Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings results on Thursday, March 19th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.07). Eton Pharmaceuticals had a negative return on equity of 2.66% and a negative net margin of 5.75%.The firm had revenue of $21.28 million for the quarter, compared to the consensus estimate of $20.58 million. Sell-side analysts predict that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current year.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.